Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Enclomiphene and Naltrexone Interaction: Avoid | Peptide Database

Compound Profiles Enclomiphene Selective Estrogen Receptor Modulator | Testosterone & Fertility Support Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Naltrexone

Opioid Antagonist | Low-Dose Anti-Inflammatory & Immune Modulation

At low doses (1-4.5 mg), naltrexone produces a brief nocturnal blockade of opioid receptors that lasts approximately 4-6 hours.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Enclomiphene with Naltrexone?

Combining Enclomiphene with Naltrexone is not recommended. Both Enclomiphene and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Naltrexone safe together?

This combination carries significant risk. Both Enclomiphene and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Naltrexone?

Both Enclomiphene and Naltrexone carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Naltrexone?

Enclomiphene has a half-life of ~10 hours and Naltrexone has a half-life of ~4 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Superdrol — share findings, ask questions, and learn from real experiences Superdrol (methyldrostanolone, also known as methasterone) is a synthetic oral anabolic-androgenic steroid derived from drostanolone (Masteron) with the addition of a 17-alpha-methyl group for oral bioavailability. It is widely regarded as one of the most potent oral anabolic steroids ever produced, delivering dramatic strength and lean mass gains in very short timeframes. Superdrol was originally marketed in the United States as a "prohormone" dietary supplement beginning in 2005 by Designer Supplements, exploiting a regulatory loophole since it was not explicitly listed as a controlled substance at the time. It was pulled from the market and subsequently classified as a Schedule III controlled substance under the Designer Anabolic Steroid Control Act of 2014. Despite its remarkable anabolic potency, Superdrol carries an extreme hepatotoxicity profile that distinguishes it from virtually all other commonly used oral steroids. Cases of severe cholestatic jaundice, liver failure, and hospitalizations have been reported even at moderate doses and short cycle lengths. It does not aromatize to estrogen, which means it does not cause water retention or gynecomastia, but this also means it provides no estrogenic support for joints, mood, or libido when used without a testosterone base. Superdrol is strictly an advanced-only compound and is not suitable for beginners under any circumstances. Superdrol exerts its effects through high-affinity binding to the intracellular androgen receptor (AR), stimulating androgen-responsive gene transcription that promotes nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle. As a DHT derivative, it cannot be aromatized by the CYP19 aromatase enzyme, so it produces no estrogenic metabolites. This accounts for the characteristic dry, hard appearance it produces without subcutaneous water retention. The 2-alpha-methyl group enhances its anabolic potency relative to its parent compound drostanolone, giving it an anabolic-to-androgenic ratio that significantly favors muscle-building effects over androgenic side effects in target tissues. The 17-alpha-methyl group allows it to survive first-pass hepatic metabolism, but this same modification is responsible for its severe hepatotoxicity. Superdrol is metabolized primarily by the liver, placing enormous stress on hepatic conjugation and bile transport pathways. It has been shown to cause dose-dependent cholestasis by disrupting bile salt export pump (BSEP) function, leading to intrahepatic bile acid accumulation. This mechanism underlies the cholestatic jaundice and hepatocellular injury that are disproportionately common with this compound compared to other 17-alpha-alkylated steroids.

Source: peptide-db.com ↗

Community Research

Join others researching PEG-MGF — share findings, ask questions, and learn from real experiences Modified IGF-1 variant with PEG attachment extending half-life from minutes to hours. Activates muscle satellite cells following mechanical stress or injury. Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. E-peptide domain exhibits distinct activity from mature IGF-1.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Oral supplementation is the most common route of administration for ecdysterone. It is typically sold as capsules or tablets containing spinach extract standardized for ecdysterone content, or as pure 20-hydroxyecdysone. Oral bioavailability is limited due to significant first-pass hepatic metabolism, which is why relatively high doses (500-1000 mg/day) are required. Cyclodextrin-complexed formulations may improve absorption. The short half-life of 4-9 hours means splitting the daily dose into two administrations is common practice. Taking ecdysterone with a fat-containing meal may enhance absorption of this lipophilic compound. General Anabolic Support / Muscle Growth 500-1000 mg/day Split into 2 doses (morning and evening) Oral with meals

Source: peptide-db.com ↗
Side effects

Common Side Effects

Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication) Hot flashes or flushing Fatigue and general malaise Mood changes (flat affect, irritability, or low mood) Decreased libido (when estrogen is suppressed too aggressively) Headache

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →